| ASSET | YEAR | % RETURN |
|---|---|---|
AXT (AXTI) | 2026 | 415% |
Erasca (ERAS) | 2026 | 396.23% |
Aehr Test Systems (AEHR) | 2026 | 390.34% |
MaxLinear (MXL) | 2026 | 320.53% |
Enliven Therapeutics (ELVN) | 2026 | 290.06% |
Immunitybio (IBRX) | 2026 | 278.22% |
Twist Bioscience (TWST) | 2026 | 264.54% |
Ichor (ICHR) | 2026 | 256.02% |
Maase (MAAS) | 2026 | 247.22% |
Definium Therapeutics (DFTX) | 2026 | 241.78% |
Veradermics (MANE) | 2026 | 236.44% |
Ultra Clean (UCTT) | 2026 | 233.78% |
P3 Health Partners (PIII) | 2026 | 227.12% |
Oruka Therapeutics (ORKA) | 2026 | 226.03% |
Spyre Therapeutics (SYRE) | 2026 | 220.24% |
10X Genomics (TXG) | 2026 | 219.01% |
Pulse Biosciences (PLSE) | 2026 | 206.65% |
Tango Therapeutics (TNGX) | 2026 | 205.88% |
Penguin Solutions (PENG) | 2026 | 193.91% |
Iridium Communications (IRDM) | 2026 | 187.63% |
Alumis (ALMS) | 2026 | 182.5% |
Hemab Therapeutics Holdings, Inc Common Stock (COAG) | 2026 | 175.89% |
Silicon Motion Technology (SIMO) | 2026 | 173.03% |
Sellas Life Sciences (SLS) | 2026 | 169.89% |
Dianthus Therapeutics (DNTH) | 2026 | 164.95% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.